SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as investors weigh recent acquisition activity against broader macroeconomic headwinds, including geopolitical tensions and fluctuating construction market sentiment. Despite the bearish pressure, the community remains actively divided, with many long-term shareholders continuing to express confidence in CEO Brad Jacobs' consolidation strategy while others closely monitor for the next M&A catalyst or integration updates.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and price appreciation following its recent NYSE listing, with investors actively debating whether the high premium over its reported net asset value is justified by its exclusive exposure to high-profile private AI companies like Anthropic and OpenAI. Community discussion is dominated by the impact of a mandatory six-month lockup period on the majority of shares, which has created a tight float and sparked intense speculation about potential for further momentum or a sharp correction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

TSLA is under significant downward pressure as investors rotate out of growth stocks amid geopolitical instability and skepticism regarding the execution of its latest AI and infrastructure initiatives. The community remains deeply divided, with some buyers viewing the current price action as a long-term accumulation opportunity, while others express frustration over the stock's recent technical breakdown and the company's dependency on speculative future projects.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is capturing significant market attention as users actively engage with its updated lending protocol, allowing them to borrow against staked SOL while simultaneously participating in its broader ecosystem of meme tokens and community-verified projects. Discussions are currently dominated by high APY lending opportunities and the ongoing expansion of its verified token list, fueling diverse sentiment ranging from strong platform loyalty to speculative debates over its long-term tokenomics.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant insider buy by Kevin Tang, which has ignited renewed speculation about a potential buyout and strategic pipeline development. The community is actively debating the company's long-term valuation, the mysterious status of the AUR200 program, and the leadership of CEO Peter Greenleaf ahead of the upcoming earnings report.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

Crane Harbor Acquisition Corp. is trending as shareholders recently approved its merger with Xanadu Quantum Technologies, a milestone expected to establish the first publicly traded photonic quantum computing company under the ticker XNDU. Community discussion is heavily focused on the deal's potential for a low-float short-term squeeze, strategic partnerships with major tech industry leaders, and potential government funding support.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

Investors are actively debating the merits of Harvest Diversified High Income Shares ETF, frequently highlighting it as a core component for income-focused portfolios and tax-efficient strategies within Canadian tax-advantaged accounts. While some community members view market dips as opportunities for accumulation, others are engaged in broader discussions regarding the performance of its underlying covered call strategy and its role in long-term wealth building.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors digest a massive Q4 booking report that significantly exceeded expectations, signaling robust long-term demand for AI-driven lithography equipment. Community discussion remains heavily focused on the company's unassailable moat as a 'foundational' AI player, with many traders debating the sustainability of current valuation highs despite strong buyback announcements and increased backlog visibility.

ETF Opportunities Trust - T-Rex 2X Inverse MSTR Daily Target ETF

T-Rex 2X Inverse MSTR Daily Target ETF

The community is actively trading the high volatility of $MSTZ, with many traders sharing their success in utilizing it as a tactical hedge or scalp against the price action of $MSTR and broader crypto market movements. Discussions highlight a split between those treating the asset as a quick day-trading instrument to capitalize on intraday pullbacks and those holding longer-term positions, while others debate the inherent risks of leveraged products in a volatile sector.

Netskope, Inc. engages in the provision of cloud based security solutions. It offers business developing analytics for visibility, policy enforcement and other cloud solutions. Its products include Netskope one SASE, Netskope one SSE, cloud access security broker, next generation secure web gateway, private access, cloud firewall, SD-WAN and skopeAI. The company was founded by Sanjay Beri, Lebin Cheng, Ravishankar Ithal, and Krishna Narayanaswamy in October 2012 and is headquartered in Santa Clara, CA.

Netskope Inc. - Ordinary Shares - Class A

Netskope is attracting significant investor interest as it trades near its IPO price, with the community actively discussing potential undervaluation, strong institutional buying, and the company's critical role in AI-native cybersecurity. Despite recent price volatility and concerns surrounding lock-up expiration, many traders view the stock as a long-term acquisition target, emphasizing its solid fundamentals and growing market share in the SASE sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a research report on Thursday...

HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for Aclaris Therapeutics in a research report issued...

Research Analysts Offer Predictions for ACRS FY2027 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a note...

Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference

Aclaris Therapeutics (NASDAQ:ACRS) outlined multiple clinical and near-term development milestones across its large-molecule and small-molecule pipeline during a presentation at the Leerink Partners...

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Aclaris Therapeutics (NASDAQ:ACRS) Announces Earnings Results, Misses Expectations By $0.01 EPS

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing...

Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference

Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company's clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer's Annual Healthcare Conference...

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +5.39% and +30.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Corcept (CORT) delivered earnings and revenue surprises of -24.53% and -20.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.16	--	--	N/A
Q4 '25	-$0.14	-$0.16	-10.55%	MISSED
Q3 '25	-$0.14	-$0.12	11.86%	BEAT
Q2 '25	-$0.13	-$0.13	2.15%	BEAT
Q1 '25	-$0.15	-$0.12	21.16%	BEAT

ACRS
Aclaris Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ACRS News

ACRSAclaris Therapeutics Inc